Volatile Week, but Green? Click to watch the new Podcast.

ARCA biopharma Stock Forecast

NASDAQ:ABIO BUY SELL

$2.51 (1.21%)

Volume: 44.754k

Closed: Jul 05, 2022

Hollow Logo Score: 1.796

ARCA biopharma Stock Forecast

BUY SELL NASDAQ:ABIO
$2.51 (1.21%)

Volume: 44.754k

Closed: Jul 05, 2022

Score Hollow Logo 1.796

ARCA biopharma Company Profile

11080 CirclePoint Road

Westminster CO 80020

720-940-2200

arcabio.com

Industry: Biotechnology

Sector: Healthcare

ARCA biopharma

Description

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE